We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.


Ana Catarina Ferreira

Project Manager

Ilia Kurochkin, PhD

CRI Computational Postdoctoral Fellow

Camila Vazquez Echegaray, PhD

Marie Curie Postdoctoral Fellow

Pedro Cunha, PhD

Postdoctoral Fellow

Luís Rocha, PhD

Postdoctoral Fellow

Liliana Oliver Rios

Postdoctoral Fellow

Peng Wei

Postdoctoral Fellow

Inês Caiado

PhD Student

Abigail Altman

PhD Student

Evelyn Halitzki

PhD Student

Diogo Cabral

PhD Student

Malavika Sreekumar Nair

Project Assistant

Mariana Gonçalves

Research Assistant

Daniel Oliveira

Research Assistant

Beatriz Lourenço Vaz

Research Assistant

Margarida Brás

Research Assistant

Alex Mateo

MSc Student

Tommaso Ballocci

MSc Student

Stefanie Weber

MSc student

Susana Pedreiro

Technician/Lab Manager


Cristiana Pires

Former Postdoctoral Fellow

Currently CEO at Asgard Therapeutics AB, Sweden

Rita Silvério-Alves

Former PhD Student

Currently Postdoc Fellow at Novo Nordisk Foundation, Center for Stem Cell Medicine, reNew, University of Copenhagen, Denmark

Fábio Rosa

Former PhD Student

Currently Head of Research at Asgard Therapeutics AB, Sweden

Alexandra Gabriela Ferreira

Former PhD Student

Currently Research Scientist at BioInvent International AB, Sweden

Andreia Gomes

Former PhD Student

Currently Global Product Manager HSC Engineering at Miltenyi Biotec, Portugal

Robin Scheuplein

Former MSc Student

Currently PhD student at ETH Zürich, Switzerland

Nina Lipjankić

Former MSc Student

Currently Research Associate at Acrivon AB, Sweden

Tasnim Zahan

Former MSc Student

Currently Process Development Technician at Immunicum AB, Sweden

Ariane Tenreiro

Former MSc Student

Currently PhD Student at Percy Knolle's Lab. Technical University of Munich, Germany

Svandís Sæmundsdóttir

Former Computational MSc Student

Currently Associate Consultant at Oracle, Sweden

Frederick Korbel

Former BSc Student

Currently PhD Student at Uwe Ohler Lab. Max-Delbrück-Center for Molecular Medicine, Germany

Luis Galán Palma

Former Erasmus Student

Currently Postdoc Fellow at Anna Bigas Lab. Hospital del Mar Institute, Barcelona, Spain


Jenny Hansson

Lund University

Proteomics. Lund, Sweden

Katharina Lahl

Lund University

Dendritic Cells. Lund, Sweden

Raquel Almeida

i3S - University of Porto

Cancer Stem Cells. Porto, Portugal

Ewa Sitnicka

Lund University

NK Cell Biology. Lund, Sweden

Johan Bengzon

Skåne University Hospital

Clinical. Neurosurgery. Lund, Sweden

Dung-Fang Lee

MD Anderson Cancer Center

Kinases and Phosphatases. Texas, U.S.A.

Kees-Jan Pronk

Skåne University Hospital

Clinical. Hematology. Lund, Sweden

Göran B Jönsson

Lund University

Melanoma. Lund, Sweden

Malin Lindstedt & Lennart Greiff

Lund University

Clinical. Head and Neck. Lund, Sweden

Cristian Bellodi

Lund University

Epitranscriptomics. Lund, Sweden

Javier Martin Gonzalez

University of Copenhagen

Transgenic Mouse Model Generation. Copenhagen, Denmark

Anna-Lena Gustavsson


Small Molecule Screening. Stockholm, Sweden

Zlatko Janeba

Czech Academy of Sciences

Medicinal Chemistry. Prague, Czech Republic

Jianwen Que

Columbia University

Lung Reprogramming. New York, U.S.A.

Inge Marie Svane

Copenhagen University Hospital

Clinical. Melanoma. Copenhagen, Denmark

Irina Agarkova

InSphero AG

Spheroids. Schlieren, Switzerland

Silvia Remeseiro

Umeå University

Chromatin Organization. Umeå, Sweden

Andreas Bender

University of Cambridge

Molecular Informatics. Cambridge, U.K.

Claudio Cantù

Linköping University

Chromatin Modification. Linköping, Sweden

Valentina Cauda

Polytechnic University of Turin

Nanoparticles. Turin, Italy

Baris Tursun

University of Hamburg

Reprograming Barriers Screening. Hamburg, Germany


Asgard Therapeutics

An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.

Blood Reprogramming Technologies

Blood Reprogramming Technologies is a biotechnology start-up focused on the use of direct cell reprogramming to generate innovative solutions for hematopoietic stem cell transplantation and blood regeneration.